Refers to a compound of formula (i) wherein: R1 and R2 are each h, alkyl, hydroxyl, haloalquilo, among others RB is H, hydroxyl, halogeno, cyano, haloalquilo, among others or is optionally substituted aryl, C5 Heterocycles such as imidazole, pyrazole isoxazole, thiazole, thiadiazole,, pirimi Dina or Benzothiazole is h V -, cyano, Nitro, nrxry, halogen, among others, RX and ry are h, hydroxylHalogen, alkyl, alquenilo, among others.Preferred compounds are: N - [4 - (2,4-difluorophenyl) - 1,3 - thiazol-2-yl] - 2 - (dimethyl [2.4 - 1.3 - 1,2,3,4 - Tetra Hydro - 5h pyrrolo [3,2-d] pyrimidin-5-yl) acetamide 2 - (dimethyl - 2.4 - 1.3 - [- 1,2,3,4 - tetrahydro - 5h pyrrolo [3,2-d] pyrimidin-5-yl) - N - (4 - [4-fluoro-3 - (trifluoromethyl) phenyl] - 1.3 - thiazol-2-yl acetamid} A 2 - (4,6 Dimethyl 5,7 - - - [4,5,6,7 tetrahydro - 1H pyrazolo [43 - D - 1 - il] pyrimidin-2-yl) - N - (4 - [3-fluoro-4 - (trifluoromethyl) phenyl] - 1.3 - thiazol-2-yl} acetamide among others. This Compound is a Derivative of pirimidindiona merged Modulator Transient Receptor Potential of the subfamily a, member 1 (TRPA1) useful for treating or Preventing a disease related to TRPA1SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 Y R2 SON CADA UNO H, HIDROXILO, ALQUILO, HALOALQUILO, ENTRE OTROS Rb ES H, HIDROXILO, CIANO, HALOGENO, HALOALQUILO, ENTRE OTROS U ES ARILO OPCIONALMENTE SUSTITUIDO, HETEROCICLOS C5 TALES COMO TIAZOL, IMIDAZOL, ISOXAZOL, PIRAZOL, TIADIAZOL, PIRIMIDINA O BENZOTIAZOL V ES H, CIANO, NITRO, -NRXRY, HALOGENO, ENTRE OTROS RX Y RY SON H, HIDROXILO, HALOGENO, ALQUILO, ALQUENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[4-(2,4-DIFLUOROFENIL)-1,3-TIAZOL-2-IL]-2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRA HIDRO-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)ACETAMIDA 2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDRO-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)-N-{4-[4-FLUORO-3-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-2-IL} ACETAMIDA 2-(4,6-DIMETIL-5,7-DIOXO-4,5,6,7-TETRAHIDRO-1H-PIRAZOLO [4,3-d]PIRIMIDIN-1-IL)-N-{4-[3-FLUORO-4-(
